Research Output per year
Fingerprint Dive into the research topics where Muhamed Baljevic is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 4 Similar Profiles
Multiple Myeloma
Medicine & Life Sciences
Acute Promyelocytic Leukemia
Medicine & Life Sciences
Qatar
Medicine & Life Sciences
Proteasome Inhibitors
Medicine & Life Sciences
Compulsive Behavior
Medicine & Life Sciences
Acute Myeloid Leukemia
Medicine & Life Sciences
Conflict of Interest
Medicine & Life Sciences
Medical Ethics
Medicine & Life Sciences
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Research Output 2008 2019
Multiple myeloma, version 1.2020 featured updates to the NCCN guidelines
Kumar, S. K., Callander, N. S., Hillengass, J., Liedtke, M., Baljevic, M., Campagnaro, E., Castillo, J. J., Chandler, J. C., Cornell, R. F., Costello, C., Efebera, Y., Faiman, M., Garfall, A., Godby, K., Holmberg, L., Htut, M., Huff, C. A., Kang, Y., Landgren, O., Malek, E. & 11 others, , Jan 1 2019, In : JNCCN Journal of the National Comprehensive Cancer Network. 17, 10, p. 1154-1165 12 p.Research output: Contribution to journal › Review article
Open Access
Multiple Myeloma
Guidelines
Aftercare
Paraproteinemias
Plasmacytoma
Pharmacodynamics and pharmacokinetics of proteasome inhibitors for the treatment of multiple myeloma
Baljevic, M. & Orlowski, R. Z., Jun 3 2019, In : Expert Opinion on Drug Metabolism and Toxicology. 15, 6, p. 459-473 15 p.Research output: Contribution to journal › Article
Pharmacodynamics
Proteasome Inhibitors
Pharmacokinetics
Multiple Myeloma
Proteasome Endopeptidase Complex
4
Citations
(Scopus)
Present and future of immunotherapy in the management of multiple myeloma
Baljevic, M. & Holstein, S. A., Jul 1 2018, In : Journal of oncology practice. 14, 7, p. 403-410 8 p.Research output: Contribution to journal › Review article
Multiple Myeloma
Immunotherapy
Transplantation
Proteasome Inhibitors
Antigen Presentation
7
Citations
(Scopus)
Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma
Baljevic, M., Zaman, S., Baladandayuthapani, V., Lin, Y. H., de Partovi, C. M., Berkova, Z., Amini, B., Thomas, S. K., Shah, J. J., Weber, D. M., Fu, M., Cleeland, C. S., Wang, X. S., Stellrecht, C. M., Davis, R. E., Gandhi, V. & Orlowski, R. Z., Jun 1 2017, In : Annals of Hematology. 96, 6, p. 977-985 9 p.Research output: Contribution to journal › Article
Multiple Myeloma
Disease Progression
Aptitude
Hepatocyte Growth Factor
ARQ 197
3
Citations
(Scopus)
Telomere length recovery: A strong predictor of overall survival in acute promyelocytic leukemia
Baljevic, M., Dumitriu, B., Lee, J. W., Paietta, E. M., Wiernik, P. H., Racevskis, J., Chen, C., Stein, E. M., Gallagher, R. E., Rowe, J. M., Appelbaum, F. R., Powell, B. L., Larson, R. A., Coutré, S. E., Lancet, J., Litzow, M. R., Luger, S. M., Young, N. S. & Tallman, M. S., Nov 1 2016, In : Acta Haematologica. 136, 4, p. 210-218 9 p.Research output: Contribution to journal › Article
Acute Promyelocytic Leukemia
Telomere
Survival
Stem Cells
Genes